放射学报告的自然语言处理评估晚期黑色素瘤患者的生存率。

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancers Pub Date : 2025-05-07 DOI:10.3390/cancers17091595
Jeeban P Das, Jordan Eichholz, Varadan Sevilimedu, Natalie Gangai, Danny N Khalil, Michael A Postow, Richard K G Do
{"title":"放射学报告的自然语言处理评估晚期黑色素瘤患者的生存率。","authors":"Jeeban P Das, Jordan Eichholz, Varadan Sevilimedu, Natalie Gangai, Danny N Khalil, Michael A Postow, Richard K G Do","doi":"10.3390/cancers17091595","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: To use natural language processing (NLP) to extract large-scale data from the CT radiology reports of patients with advanced melanoma treated with immunotherapy and to determine whether liver metastases affect survival. <b>Methods</b>: Patient criteria (M1 disease subclassified into M1a, M1b, or M1c) as well as alternative criteria (M1 with advanced melanoma, imaged with CT chest, abdomen, and pelvis from July 2014-March 2019) were included retrospectively. NLP was used to identify metastases from CT reports, and then patients were classified according to American Joint Committee on Cancer (AJCC) staging disease subclassified into M1L+ or M1L-, indicating whether liver metastases were present or not). Statistical analysis included constructing Kaplan-Meier survival curves and calculating hazard ratios (HRs). <b>Results</b>: 2239 patients were included (mean age, 63 years). Whether using AJCC or alternative criteria, overall survival (OS) was poorest for M1L+ (entire cohort median OS, 0.69 years [95% CI: 0.60-0.82]; immunotherapy cohort median OS, 1.4 years [95% CI: 0.92-2.0]) compared to M1L- (entire cohort median OS, 1.8 years [95% CI: 1.4-2.2]; immunotherapy cohort median OS; M1L-, 2.9 years [95% CI: 2.3-3.9]). The median HR for M1L+ (median HR, 5.35 [95% CI: 4.59-6.24]) was higher than that for M0 (<i>p</i> < 0.001). The median HR for M1L+ (median HR, 2.13 [95% CI: 1.65-2.64]) was higher than that for M0 (<i>p</i> < 0.01). <b>Conclusions</b>: Patients with advanced melanoma, particularly those with liver metastases, demonstrated inferior survival, even when treated with immunotherapy.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071518/pdf/","citationCount":"0","resultStr":"{\"title\":\"Natural Language Processing of Radiology Reports to Assess Survival in Patients with Advanced Melanoma.\",\"authors\":\"Jeeban P Das, Jordan Eichholz, Varadan Sevilimedu, Natalie Gangai, Danny N Khalil, Michael A Postow, Richard K G Do\",\"doi\":\"10.3390/cancers17091595\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objectives</b>: To use natural language processing (NLP) to extract large-scale data from the CT radiology reports of patients with advanced melanoma treated with immunotherapy and to determine whether liver metastases affect survival. <b>Methods</b>: Patient criteria (M1 disease subclassified into M1a, M1b, or M1c) as well as alternative criteria (M1 with advanced melanoma, imaged with CT chest, abdomen, and pelvis from July 2014-March 2019) were included retrospectively. NLP was used to identify metastases from CT reports, and then patients were classified according to American Joint Committee on Cancer (AJCC) staging disease subclassified into M1L+ or M1L-, indicating whether liver metastases were present or not). Statistical analysis included constructing Kaplan-Meier survival curves and calculating hazard ratios (HRs). <b>Results</b>: 2239 patients were included (mean age, 63 years). Whether using AJCC or alternative criteria, overall survival (OS) was poorest for M1L+ (entire cohort median OS, 0.69 years [95% CI: 0.60-0.82]; immunotherapy cohort median OS, 1.4 years [95% CI: 0.92-2.0]) compared to M1L- (entire cohort median OS, 1.8 years [95% CI: 1.4-2.2]; immunotherapy cohort median OS; M1L-, 2.9 years [95% CI: 2.3-3.9]). The median HR for M1L+ (median HR, 5.35 [95% CI: 4.59-6.24]) was higher than that for M0 (<i>p</i> < 0.001). The median HR for M1L+ (median HR, 2.13 [95% CI: 1.65-2.64]) was higher than that for M0 (<i>p</i> < 0.01). <b>Conclusions</b>: Patients with advanced melanoma, particularly those with liver metastases, demonstrated inferior survival, even when treated with immunotherapy.</p>\",\"PeriodicalId\":9681,\"journal\":{\"name\":\"Cancers\",\"volume\":\"17 9\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071518/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/cancers17091595\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17091595","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:利用自然语言处理(NLP)从免疫治疗晚期黑色素瘤患者的CT放射学报告中提取大规模数据,以确定肝转移是否影响生存。方法:回顾性纳入患者标准(M1疾病细分为M1a、M1b或M1c)以及替代标准(M1伴晚期黑色素瘤,2014年7月至2019年3月胸部、腹部和骨盆CT成像)。采用NLP从CT报告中识别转移,然后根据美国癌症联合委员会(AJCC)分期将患者分为M1L+或M1L-,表明是否存在肝转移)。统计分析包括构建Kaplan-Meier生存曲线和计算风险比(hr)。结果:纳入2239例患者(平均年龄63岁)。无论是使用AJCC还是其他标准,M1L+患者的总生存期(OS)最低(整个队列中位OS, 0.69年[95% CI: 0.60-0.82];免疫治疗队列中位OS, 1.4年[95% CI: 0.92-2.0])与M1L-(整个队列中位OS, 1.8年[95% CI: 1.4-2.2];免疫治疗队列中位OS;M1L-, 2.9年[95% CI: 2.3-3.9])。M1L+组的中位HR(中位HR, 5.35 [95% CI: 4.59-6.24])高于M0组(p < 0.001)。M1L+的中位HR(中位HR, 2.13 [95% CI: 1.65-2.64])高于M0 (p < 0.01)。结论:晚期黑色素瘤患者,特别是肝转移患者,即使接受免疫治疗,生存率也较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Natural Language Processing of Radiology Reports to Assess Survival in Patients with Advanced Melanoma.

Background/Objectives: To use natural language processing (NLP) to extract large-scale data from the CT radiology reports of patients with advanced melanoma treated with immunotherapy and to determine whether liver metastases affect survival. Methods: Patient criteria (M1 disease subclassified into M1a, M1b, or M1c) as well as alternative criteria (M1 with advanced melanoma, imaged with CT chest, abdomen, and pelvis from July 2014-March 2019) were included retrospectively. NLP was used to identify metastases from CT reports, and then patients were classified according to American Joint Committee on Cancer (AJCC) staging disease subclassified into M1L+ or M1L-, indicating whether liver metastases were present or not). Statistical analysis included constructing Kaplan-Meier survival curves and calculating hazard ratios (HRs). Results: 2239 patients were included (mean age, 63 years). Whether using AJCC or alternative criteria, overall survival (OS) was poorest for M1L+ (entire cohort median OS, 0.69 years [95% CI: 0.60-0.82]; immunotherapy cohort median OS, 1.4 years [95% CI: 0.92-2.0]) compared to M1L- (entire cohort median OS, 1.8 years [95% CI: 1.4-2.2]; immunotherapy cohort median OS; M1L-, 2.9 years [95% CI: 2.3-3.9]). The median HR for M1L+ (median HR, 5.35 [95% CI: 4.59-6.24]) was higher than that for M0 (p < 0.001). The median HR for M1L+ (median HR, 2.13 [95% CI: 1.65-2.64]) was higher than that for M0 (p < 0.01). Conclusions: Patients with advanced melanoma, particularly those with liver metastases, demonstrated inferior survival, even when treated with immunotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信